Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD
Status:
Completed
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of allopregnanolone, a
naturally occurring brain steroid, in mild cognitive impairment and early Alzheimer's disease
participants. The primary goal is to determine the maximally tolerated dose.